Short Interest in Axsome Therapeutics Inc (NASDAQ:AXSM) Decreases By 6.0%

Axsome Therapeutics Inc (NASDAQ:AXSM) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totalling 5,030,000 shares, a drop of 6.0% from the December 15th total of 5,350,000 shares. Currently, 17.9% of the shares of the stock are sold short. Based on an average daily volume of 1,350,000 shares, the days-to-cover ratio is presently 3.7 days.

Axsome Therapeutics stock traded up $0.21 during midday trading on Thursday, reaching $90.90. 24,052 shares of the stock traded hands, compared to its average volume of 1,498,050. The company has a 50-day simple moving average of $75.93 and a two-hundred day simple moving average of $37.76. Axsome Therapeutics has a 12-month low of $7.63 and a 12-month high of $109.94. The firm has a market cap of $3.12 billion, a PE ratio of -78.69 and a beta of 3.39. The company has a current ratio of 2.39, a quick ratio of 2.39 and a debt-to-equity ratio of 2.80.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.15). Equities research analysts anticipate that Axsome Therapeutics will post -1.77 earnings per share for the current year.

A number of equities analysts have commented on the stock. SunTrust Banks boosted their target price on shares of Axsome Therapeutics to $140.00 and gave the stock a “buy” rating in a report on Thursday, January 2nd. Zacks Investment Research upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, November 19th. Guggenheim increased their price target on Axsome Therapeutics from $65.00 to $48.00 in a report on Wednesday, December 4th. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $165.00 price target (up from $139.00) on shares of Axsome Therapeutics in a report on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and set a $200.00 price target (up from $170.00) on shares of Axsome Therapeutics in a report on Tuesday, December 24th. Two research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $99.80.

A number of institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can purchased a new stake in Axsome Therapeutics during the second quarter valued at about $52,000. Schroder Investment Management Group bought a new stake in Axsome Therapeutics during the 2nd quarter worth about $76,000. Ladenburg Thalmann Financial Services Inc. lifted its position in Axsome Therapeutics by 41.2% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,800 shares of the company’s stock worth $124,000 after buying an additional 1,400 shares in the last quarter. Metropolitan Life Insurance Co NY bought a new stake in Axsome Therapeutics during the 3rd quarter worth about $171,000. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in Axsome Therapeutics during the 2nd quarter worth about $281,000. Institutional investors own 54.64% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.

See Also: How Do I Invest in Dividend Stocks

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.